Yang Wenhan, Pan Zhiyu, Zhang Jiacheng, Wang Lian, Lai Ju, Fan Kai, Zhu Jingjing, Liu Qian, Dai Yalei, Zhou Jieyu, Wu Shuhui, Gao Zhengliang, Yu Shaoqing
Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Department of Anesthesiology, Shanghai Gongli Hospital, Naval Military Medical University, Shanghai, China.
Cell Transplant. 2025 Jan-Dec;34:9636897251325673. doi: 10.1177/09636897251325673. Epub 2025 Apr 3.
We previously found that intravenous injection of extracellular vesicles (EVs) from human adipose tissue-derived stem cells (hADSC) could ameliorate allergic rhinitis (AR) in mice through immunomodulatory effects. In clinical trials, nasal delivery has been an attractive treatment for AR. We sought to determine whether there are differences in the therapeutic effects between caudal injection and their combination. We treated AR mice with ADSC-EVs via caudal vein, nasal cavity, or both. After treatment, the mice were re-sensitized and the indices of behavior, nasal mucosa morphology, and cytokine secretion of the mice under different modes of administration were calculated. The resultes show that tail vein, nasal, and combined administration could effectively relieve the inflammatory infiltration of the nasal mucosa of mice, reduce the secretion of IgE, IL-4, and other inflammatory factors, and alleviate the Th1/Th2 imbalance. Injection and nasal delivery, as well as their combination, effectively alleviated the symptoms of rhinitis in mice. Nasal administration has a better therapeutic effect when the inflammatory response is mild. It could be speculated that ADSC-EVs have excellent properties in the treatment of AR, and modes of administration can be selected for different stages of treatment in clinical therapy.
我们先前发现,静脉注射源自人脂肪组织干细胞(hADSC)的细胞外囊泡(EVs)可通过免疫调节作用改善小鼠的过敏性鼻炎(AR)。在临床试验中,鼻腔给药一直是治疗AR的一种有吸引力的方法。我们试图确定尾静脉注射及其联合使用在治疗效果上是否存在差异。我们通过尾静脉、鼻腔或两者联合的方式用ADSC-EVs治疗AR小鼠。治疗后,使小鼠再次致敏,并计算不同给药方式下小鼠的行为指标、鼻黏膜形态以及细胞因子分泌情况。结果表明,尾静脉注射、鼻腔给药以及联合给药均可有效减轻小鼠鼻黏膜的炎性浸润,减少IgE、IL-4等炎性因子的分泌,并缓解Th1/Th2失衡。注射给药、鼻腔给药及其联合使用均有效减轻了小鼠的鼻炎症状。在炎症反应较轻时,鼻腔给药具有更好的治疗效果。可以推测,ADSC-EVs在治疗AR方面具有优异的特性,在临床治疗中可针对不同治疗阶段选择给药方式。